Global CRO Footprint IHMA provides end-to-end antimicrobial development capabilities with laboratories in the US and Europe, enabling cross-border studies and streamlined regulatory support. This positions IHMA as a single partner for biotech and pharmaceutical clients seeking discovery through post-marketing testing, including surveillance studies and clinical trials.

Surveillance & Trials IHMA specializes in surveillance studies and clinical trials for antimicrobials, differentiating it in the CRO market with robust data and regulatory readiness. Target diagnostics firms and mid-market pharma seeking validated antimicrobial testing and regulatory-compliant study execution.

Industry Engagement IHMA's active participation in leading antimicrobial conferences signals growth opportunities through sponsorships and targeted outreach. Leverage Gordon Research Conference and ESCMID events to generate high-quality leads and build partnerships with researchers and developers.

Tech-Enabled Growth A modern tech stack including Salesforce and analytics platforms supports scalable client management, data integration, and rapid reporting. Upsell opportunities include integrated data platforms, real-time trial dashboards, and marketing automation for client recruitment and engagement.

Market Position Positioned as a mid-sized, specialized antimicrobial development provider, IHMA can upsell to mid-market pharma and biotech clients needing niche antimicrobial services, regulatory guidance, and post-marketing surveillance. Potentially expand service lines into broader regulatory consulting and long-term post-marketing support.